Wikipedia

BriLife

(Redirected from IIBR-100)

BriLife, also known as IIBR-100, is a replication-competent recombinant VSV viral vectored COVID-19 vaccine candidate.[2][3][4][5] It was developed by the Israel Institute for Biological Research (IIBR).[2][6][7] The IIBR partnered with the US-based NRx Pharmaceuticals to complete clinical trials and commercialize the vaccine.[8][9] A study conducted in hamsters suggested that one dose of the vaccine was safe and effective at protecting against COVID-19.[10][4]

BriLife
Reuven Rivlin and the first person to receive the BriLife vaccine look at the viewer alongside two nurses. The flag of Israel sits in the background.
The former President of Israel, Reuven Rivlin, with the first vaccinator in Phase B of the IIBR-100 vaccine of the Israel Institute for Biological Research, at the Barzilai Medical Center.
Vaccine description
TargetSARS-CoV-2
Vaccine typeViral vector
Clinical data
Other namesBrilife
Routes of
administration		Intramuscular
ATC code
  • None
Identifiers
CAS Number

References

edit
  1. ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
  2. ^ a b Karpiński TM, Ożarowski M, Seremak-Mrozikiewicz A, Wolski H, Wlodkowic D (1 January 2021). "The 2020 race towards SARS-CoV-2 specific vaccines". Theranostics. 11 (4): 1690–1702. doi:10.7150/thno.53691. PMC 7778607. PMID 33408775.
  3. ^ Bezbaruah R, Borah P, Kakoti BB, Al-Shar'I NA, Chandrasekaran B, Jaradat DM, et al. (2021). "Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19". Frontiers in Molecular Biosciences. 8: 635337. doi:10.3389/fmolb.2021.635337. PMC 8082173. PMID 33937326.
  4. ^ a b Pushparajah D, Jimenez S, Wong S, Alattas H, Nafissi N, Slavcev RA (March 2021). "Advances in gene-based vaccine platforms to address the COVID-19 pandemic". Advanced Drug Delivery Reviews. 170: 113–141. doi:10.1016/j.addr.2021.01.003. PMC 7789827. PMID 33422546.
  5. ^ Venkadapathi J, Govindarajan VK, Sekaran S, Venkatapathy S (9 June 2021). "A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials". Frontiers in Molecular Biosciences. 8: 637378. doi:10.3389/fmolb.2021.637378. PMC 8219860. PMID 34179072.
  6. ^ Clinical trial number NCT04608305 for "Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults" at ClinicalTrials.gov
  7. ^ Scarabel L, Guardascione M, Dal Bo M, Toffoli G (March 2021). "Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19". International Journal of Infectious Diseases. 104: 441–451. doi:10.1016/j.ijid.2021.01.035. PMC 7816887. PMID 33476760.
  8. ^ Rabinovitch A, Williams D (12 July 2021). Grebler D (ed.). "Israel partners with NRx Pharmaceuticals to commercialize COVID vaccine". Reuters. Retrieved 10 November 2021.
  9. ^ "Israeli-produced vaccine shipped to Georgia for Phase II trial". i24 News. 15 August 2021. Retrieved 10 November 2021.
  10. ^ Yahalom-Ronen Y, Tamir H, Melamed S, Politi B, Shifman O, Achdout H, et al. (December 2020). "A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge". Nature Communications. 11 (1): 6402. doi:10.1038/s41467-020-20228-7. PMC 7745033. PMID 33328475.
edit
 
Scholia has a profile for BriLife (Q100694835).
 
Wikimedia Commons has media related to BriLife.


 

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.

 

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=BriLife&oldid=1256024376"